You are here

New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation’s Blood Volume Analyzer (BVA-100®) in Critical Care

NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new research from the University of Hawaii John A. Burns School of Medicine showing improved ease of use with the BVA-100 test by reducing the number of blood samples and that direct blood volume analysis provides clinicians with important information to inform better treatment decisions in the critically-ill. Three new studies were presented during the 48th Annual Society of Critical Care Medicine Congress in San Diego, CA.
Friday, February 22, 2019 - 08:37